Lymphogranuloma Venereum

In developing countries, a presumed diagnosis of LGV is usually made based on clinical findings. In industrialized countries, LGV diagnosis is still difficult owing to limitations in commercially available tests and is typically either presumed based on clinical findings or is made through specialized LGV testing at CDC or other specialized laboratories. Serologic tests for C. trachomatis, including complement fixation (CF) and microimmunofluorescence (MIF) tests, are not standardized and do not reliably differentiate between LGV and non-LGV C. trachomatis strains; higher antibody titers (CF titers >1:64 and MIF titers >1:256) are strongly suggestive of LGV when accompanied by compatible clinical findings but are not confirmatory. Detection of C. trachomatis by culture or NAATs from anogenital specimens also does not differentiate LGV from non-LGV strains, and therefore the only means to confirm LGV is to have CDC or a specialized laboratory perform OmpA typing on the C. trachomatis strain to demonstrate one of the LGV OmpA types. If buboes are present, C. trachomatis may be detected in a bubo aspirate, which would be highly suggestive of LGV in this clinical context; however, confirmation by OmpA typing should still be performed if possible. Treatment of LGV should not be delayed while awaiting the results of LGV testing.

  • Contact
  • Category: Infectious diseases